By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Natural disasters in Japan, Australia, and New Zealand and political unrest in Egypt contributed to essentially flat revenues for the first quarter, Qiagen said after the close of the market on Wednesday.

For the three months ended March 31, the molecular diagnostics and sample prep technologies firm reported revenues of $264.3 million, compared to $264.4 million a year ago, and short of Wall Street estimates of $270.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.